

**GJPB**

# **German Journal of Pharmaceuticals and Biomaterials**

**Zeitschrift für Pharmazeutika und Biomaterialien**

## Table of Contents



- Aim & Scope
- Audience/Contributors
- Types of paper
- Article processing charges
- Copyright policy
- Plagiarism policy
- Retraction policy
- Manuscript preparation
- Disclaimer/ Editorial policy
- Authorship/ Author disclosure & Ethical approvals

ISSN Print: 2750-624X  
ISSN Online: 2750-6258

## Aim & Scope

**German Journal of Pharmaceuticals and Biomaterials (GJPB)** is an interdisciplinary peer reviewed open access scientific journal, publishes high-quality experimental and theoretical research that contributes significantly on all aspects of pharmaceutical sciences and biomaterials and their related subjects including their applications in human (covering experimental and clinical therapeutics). The mission is to publish scientific work that has followed laborious methodologies and to contribute to progress and development in both pharmaceuticals and biomaterials.

Scientific areas within the scope of this journal include but are not limited to pharmaceuticals (all aspects of formulations and drug delivery systems, including oral, pulmonary, nasal, parenteral and transdermal delivery) and biopharmaceuticals, including pharmaceutical biotechnology products, biochemistry and microbiology, pharmacology and toxicology, applied separation science (covers all areas of analytical/chromatography techniques), natural product drug discovery, medicinal chemistry, and bioactive polymers. This journal is also interested in work that addresses biomaterials but is not limited to covering all aspects of biomaterials with broad range of physical, biological and chemical sciences that support the design of biomaterials and the clinical/scientific disciplines in which they are used.

**Country of Publication:** Germany

**Frequency:** Quarterly (4 issues/year)

## Audience/Contributors

Researchers, Students, Professional, Clinicians, those who are working in academics and industries.

## Types of papers

The following types of papers are considered by the Editorial Board: Letters, Research Articles, Review Articles (including Mini-reviews and Critical reviews), Expert Opinions, Short Communications, Editorial Commentary, Case Studies or Case Reports.

## Manuscript processing and review speed

This journal operates a **double-blind** peer review process. All submitted manuscripts will be firstly evaluated by the Commissioning Editor for suitability of the manuscript. Papers considered appropriate are then sent to a minimum of two expert reviewers to evaluate the scientific quality of the paper. The Editor-in-Chief or Commissioning Editor/Handling Editor is responsible for the final decision concerning acceptance or rejection of articles. The overall review process takes 50 days.

Url: [www.gjpb.de](http://www.gjpb.de)

---

### **Open access policy**

GJPB has adopted the open access policy in order to ensure the maximum exposure of GJPB contents. All the articles published in GJPB are made freely available online immediately after publication in an easily readable format, without any subscription fees. All the published articles are licensed under a Creative Commons Attribution License (CC BY 4.0), which permits the users to read, download, copy, distribute, print, or link the full text articles in this journal without asking prior permission from the publisher or the author, as long as appropriate credit given to the original authors. Read detailed license information here: <https://creativecommons.org/licenses/by/4.0/>

---

### **Article processing charges**

This journal does not charge any submission or article processing fee.

---

### **Copyright policies**

All the articles published in GJPB are distributed under a creative common's attribution 4.0 International license (CC BY 4.0). Author(s) are allowed to hold the copyright of their work which means the author (s) do not need to transfer the copyright of their work to the journal. Read detailed license information here: <https://creativecommons.org/licenses/by/4.0/>.

#### **You are free to:**

**Share** - copy and redistribute the material in any medium or format

**Adapt** - remix, transform, and build upon the material for any purpose, even commercially.

#### **Under the following terms:**

**Attribution** - You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

**No additional restrictions** - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

---

### **Plagiarism policy**

The authors must assure the originality of their work while preparing a manuscript draft. If authors have used the work and/or words of others this must be properly cited or quoted in the manuscript. All the articles submitted to GJPB will be screened for plagiarism using iThenticate (online plagiarism detection software). In case, Plagiarism / Similarity Index (score below 20% is acceptable) is detected during the entire process, such manuscript(s) will be rejected immediately or the author will be asked to amend it. The handling editor makes the final choice. If the plagiarism is confirmed/proven after publication, such manuscript(s) will be retracted from the journal and an appropriate statement will be placed in this regard and strict action will be taken against authors, which includes but is not limited to debarring the authors from publication in the future. We can bring such case(s) in notice of author's funding agencies, author's institutes (where they work) and to the original authors whose work has been plagiarized. Committee on publication ethics (COPE) shall also be considered while dealing with plagiarism complaints.

Visit: <https://publicationethics.org/> or

<https://publicationethics.org/resources/flowcharts/plagiarism-submitted-manuscript>

---

### **Retraction policy**

GJPB follow the COPE Retraction Guidelines. Visit: <https://publicationethics.org/retraction-guidelines>

---

### **Disclaimer/ Editorial policy**

The author(s) of each article appearing in this Journal is/are solely responsible for the content thereof; neither the GJPB nor its editors or publisher or anyone else involved in creating, producing or distribution assumes any liability or responsibility for the accuracy, completeness, or usefulness of any information provided in the Journal, nor shall they be liable for any direct, indirect, incidental, special, consequential or

punitive damages arising out of the use of the GJPB. Author(s) is/are responsible for all the statements made in their work and should be willing to defend them publicly, if challenged.

Authors should prepare their manuscripts submitted to the journal exactly according to the instructions given. Manuscripts which do not follow the GJPB guidelines may be returned to the authors for revision or be rejected. The journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication. Manuscripts and figures are not returned to the authors, not even upon rejection of the paper.

---

#### **Manuscript withdrawal policy**

The author is allowed to withdraw the manuscript if manuscript has not been formally published.

---

#### **Permissions for reproduced or adapted material within your article**

Original content does not require any permission to publish, however authors should ensure they cite any data sources used to create the content. In case a figure or a table has been published previously (even if you were the author), acknowledge the original source and submit written permission from the copyright holder to reproduce the material where necessary.

---

#### **Manuscript preparation**

The manuscript should be typed, double-spaced on standard A4 sized paper (8.5" x 11") with 1" margins on all sides. Times New Roman font 12 pt and 1.15 line spacing between paragraphs should be used. The fonts used in the text, as well as graphics, should be restricted to Times New Roman, Symbol and Zapf Dingbats. **Please note that figures and tables must be included in the manuscript as close as possible to where they are first quoted.**

---

#### **Covering letter**

A cover letter includes the Journal name, manuscript's title, statement that your paper has not been previously published and is not currently under consideration by another journal, statement that authors do have any conflict of interest, contact information of the corresponding author, indicate clearly if color should be used for any figures in print and **suggest 2 to 3 reviewers with contact details**.

Reviewers are selected through identification of their relevant expertise via their recent publications and as accessed through indices such as PUBMED and MEDLINE. Authors may also recommend reviewers, but reviewer selection is ultimately at the editor's discretion.

---

#### **Title page**

The title page should be separated from main manuscript and contain a title of the article followed by the names and affiliations of the authors. The affiliation should comprise the department, institution, city, and state (or nation) and should be typed as a footnote to the author's name. One author should be identified as the corresponding author. The corresponding author must indicate his or her complete mailing address, office/fax number, and email address at the lower left of the title page.

Authors must include Acknowledgements, Funding details and Declaration/conflict of interest disclosures at the end of the title page.

---

#### **Article structure**

---

##### **Article title**

Authors must include the title of the article in the main manuscript.

##### **Abstract**

The abstract should not contain more than 250 words and should provide brief details about **background, objectives, methods, key findings and conclusions**. The abstract must be followed by four to six keywords.

##### **Introduction**

An introduction should provide a background to the study and should clearly state the specific aims of the study avoiding a detailed literature survey or a summary of the results.

### **Materials and methods**

Please provide concise but complete information about the material and the analytical, statistical, and experimental procedures used. This part should be as clear as possible to enable other scientists to repeat the research presented. The use of subheadings to divide the text is encouraged. Primary headings should be in bold capital letters. Secondary or subheadings should be in bold sentence case. Third level subheadings should be in Italicized sentence case. In the case of animal/human experiments or clinical trials, authors must give the details of ethical approval number.

### **Results**

Results should be clear and concise. Tables and Figures should be self-explanatory.

### **Discussion**

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations of published literature.

### **Conclusions**

A brief conclusions section should summarise the salient findings of the study. Authors are strongly advised to emphasise the contribution made to the field by their study in this section.

### **Acknowledgements**

Acknowledgements must be given in a separate section at the end of the title page and therefore should not be included in the main manuscript.

### **Funding details**

Authors should declare all applicable financial supports and sponsorship.

### **Declaration/ conflict of interest disclosures**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. A declaration of interest statement should be given in the title page file. If there are no interests to declare then please state this: '**Declarations of interest: none**'.

GJPB is committed to following ICMJE recommendations. Please follow the link to read the detailed ICMJE recommendations for disclosure of financial and non-financial relationships and activities, and conflicts of interest.

<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/author-responsibilities--conflicts-of-interest.html>

### **Tables**

Tables should be numbered with Roman numerals according to their sequence in the text, and have a short self-explanatory heading. Use SI units. Authors should keep in mind that tables that fit onto one printed page are preferred. Tables should be provided as a Microsoft Word document and must be editable.

### **Figures**

All figures and tables must be submitted in an editable format. For figures that will be included without editing (i.e., photos, imaging data, etc.) please submit in .jpeg or .tiff format. Other figures (i.e., graph or bar charts) should ideally be provided in Microsoft Word/Microsoft Excel/.jpeg/.tiff format.

- **Resolution:** Figure resolution must be as high as possible, ideally 300 dpi or higher for jpeg or tiff format. Images that are blurred or illegible will not be accepted.
- **Font:** If possible, please use Times new Roman 8pt.
- **Abbreviations:** All abbreviations used within figures/tables must be defined in the legend (even if previously defined in the body of the manuscript).
- Ensure that each figure/table has a caption. A caption should comprise a brief title.

### **Graphical Abstract**

Authors are required to submit a color graphical abstract, in single .jpeg or .tiff image that visually represents the key findings of your article.

### Reference style

References in the text are cited sequentially by number in square brackets, i.e., [15]. All citations in the text must appear in the reference list and vice versa. At the end of the manuscript, references should be listed in numerical order as they appear in the text. Journal titles should be abbreviated in accordance with the standard approved abbreviations used by PubMed. State the references according to the format of the following examples:

- Author's names should appear without full stops in their initials.
- If there are more than six authors, list the first six authors, followed by et al.
- All references mentioned in the Reference List are cited in the text, and vice versa

All authors are required to follow the ICMJE requirements of 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals'. please refer to ICMJE Guidelines

([http://www.icmje.org/recommendations/archives/2008\\_urm.pdf](http://www.icmje.org/recommendations/archives/2008_urm.pdf) or  
(<http://www.icmje.org> or [http://www.nlm.nih.gov/bsd/uniform\\_requirements.html](http://www.nlm.nih.gov/bsd/uniform_requirements.html)).

### Articles in journals

---

#### Reference to a journal publication

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

#### Organization as author

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40(5):679-86.

#### Article retracted

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2000;61(12):909-11.

Retraction in: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2002;63(2):169.

### Reference to a books and monographs

---

#### Personal author(s)

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.

#### Chapter in a book

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

#### Conference proceedings

Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

#### Conference paper

Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.

#### Dissertation

Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002.

#### Patent

Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.

## **Unpublished material**

---

### **Forthcoming and Preprints**

(Note: NLM prefers "Forthcoming" rather than "In press" because not all items will be printed.)

Tian D, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. Proc Natl Acad Sci U S A. Forthcoming 2002.

Alvarez R. Near optimal neural network estimator for spectral x-ray photon counting data with pileup. arXiv:1702.01006v1 [Preprint]. 2017 [cited 2017 Feb 9]: [11 p.]. Available from: <https://arxiv.org/abs/1702.01006>

## **Authorship/Author disclosure**

---

All the authors in a manuscript are equally responsible for the technical information communicated to the journal. Thus, it is necessary that all authors must read and approve the final version of the manuscript before submitting it to the journal. All named authors must have made an active contribution to the conception and design and/or analysis and interpretation of the data and/or the drafting of the paper and all must have critically reviewed its content and have approved the final version submitted for publication. Participation solely in the acquisition of funding or the collection of data does not justify authorship.

GJPB follows the definition of authorship given by the **International Committee of Medical Journal Editors (ICMJE)**. The ICMJE recommends that authorship be based on the following 4 criteria:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Authors should meet all the above four conditions. Please download and fill the Authorship Contribution Form, authors are required to upload the duly filled and signed form under the additional/other files section, during manuscript submission. They can also send it by email to [editor@gjpb.de](mailto:editor@gjpb.de)

## **Ethical approvals**

---

### **Patient Rights**

Patients have a right to privacy; thus, all the studies should be conducted with informed consent. No identifying information should be published in written descriptions and photographs unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. When informed consent has been obtained, it should be indicated in the article. Investigations with human subjects must follow the ethical standards formulated in the **Helsinki Declaration** of 1964, revised in 2013.

<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

### **Animal Rights**

Animal experiments must follow the ethical standards for the care and use of laboratory animals. The article involved the animal experiments must seek approval(s) from the appropriate Ethical Committee in accordance with the "**Guide for the Care and Use of Laboratory Animals**" and **ARRIVE** guidelines.

(<https://www.ncbi.nlm.nih.gov/books/NBK54050/> or <https://arriveguidelines.org/>)

All the experiments must have obtained the appropriate institutional approval for studies involving data relating to human or animal experimental investigations, and is described within the article in the manuscript or in disclosure section.

## **Clinical trials**

---

Clinical trials must follow the ICMJE guidelines. Please refer to ICMJE Guidelines.

<http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>

### **Duties of reviewers**

---

Reviewers must ensure that experiments were conducted correctly and objectively with proper ethical considerations and give their final recommendations based on a valid and reasonable interpretation of the results. If a designated reviewer feels that the research topic/article is out of his scope and have any relationships with authors or previously published work with authors, he/she must inform the Editor-in-Chief or Commissioning editor and must not take part in the review process. Reviewers should treat the manuscripts as a confidential document. Reviewers must not share and discuss the manuscripts/research topics with others and are not allowed to use any kind of information/data/ideas for personal research. There shall be no personal criticism to the author. Reviewers must express their opinions with supporting arguments.

**Please see additional guidelines for reviewers issued by:**

Committee on Publication Ethics (COPE)

<https://publicationethics.org/resources/guidelines-new/cope-ethical-guidelines-peer-reviewers>

<https://publicationethics.org/core-practices>

**International Committee of Medical Journal Editors (ICMJE)**

<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/responsibilities-in-the-submission-and-peer-review-process.html#three>

<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/author-responsibilities--conflicts-of-interest.html>

## Editorial Board

### German Journal of Pharmaceuticals and Biomaterials Zeitschrift für Pharmazeutika und Biomaterialien

#### Editor-in-Chief

Dr. med. Dietwald Dönges  
Biebertal, Germany

#### Deputy Editor-in-Chief

Prof. Dr. Eliana B. Souto  
Department of Pharmaceutical Technology  
Faculty of Pharmacy of University of Porto  
Porto, Portugal

#### Assistant Editor

Dr. Mahboubeh Nabavinia  
Center for Regenerative Medicine  
Abigail Wexner Research Institute, Nationwide Children's Hospital,  
Columbus, OH, USA  
Interest: *Biomaterials and Nanomedicine*

#### Commissioning Editor

Dr. Gurinder Singh  
Pharmaceutical Sciences and Nanomedicine  
Hamburg, Germany  
Interest: *Nanomedicine and Drug delivery systems*

#### Editorial Consultants

##### **Dr. Gregory R Wiedman**

Assistant Professor  
Department of Chemistry and Biochemistry  
Seton Hall University, New Jersey, USA  
Interest: *Antimicrobial Materials, Drug Synergy, Peptide-based Materials, Aptamers and Chemical Biology*

##### **Dr. Vladimir Mulens-Arias**

Integrative Biomedical Materials and Nanomedicine Lab  
Department of Experimental and Health Sciences (DCEXS), Pompeu Fabra University, PRBB, Barcelona, Spain  
Interest: *Nanomedicine and Nanoimmunotherapy*

##### **Dr. Shadi Sarahroodi**

Assistant professor  
Department of Pharmacology-Toxicology, School of Pharmacy and Pharmaceutical Sciences  
Tehran Medical sciences Islamic Azad University (IAUPS), Tehran, Iran  
Interest: *Behavioral neuropharmacology and Pharmacoepidemiology*

##### **Prof. B.G. Shivananda**

Registrar  
Karnataka State Pharmacy Council, Bangalore, India

##### **Dr. Nuray ARI**

Professor, Dept of Pharmacology, Faculty of Pharmacy  
Cyprus Health and Social Sciences University, Güzelyurt, Cyprus  
Interest: *Pharmacology and Diabetes models*

##### **Dr. Hirofumi Takeuchi**

Professor Emeritus  
Gifu Pharmaceutical University, Gifu, Japan  
Interest: *Dosage form design, Powder technology, Liposomes and Colloidal drug delivery systems*

##### **Mr. Haseeb Anwar Dad (Ph.d)**

Department of Pharmaceutical Sciences  
University of Milan, Italy  
Interest: *Transdermal drug delivery systems, Biomaterials and Stem cell-based tissue regeneration*

## Contents

### Front Matter

- GJPB Editor

### Research Articles

- Polysorbate 80 – Modulated nanocrystallization for enhancement of griseofulvin solubility  
– Emmanuel O. Olorunsola, Sifon U. Ekpeowo, Mumuni A. Momoh, Michael U. Adikwu..... 1 – 7
- Formulation development and in-vitro evaluation of floating sintered matrix tablets of Cefpodoxime Proxetil using carnauba wax  
– Shailaja Thoudoju, Asema Sultana, Latha Kukati, Naseeb Basha Shaik, Aisha Rahman, Ahmed Unisha Affrin Shaik, Preeti Kulkarni..... 8 – 18
- Venonia amygdalina leaf extract - mediated redox synthesis of silver nanoparticles: Characterization and antimicrobial activity  
– Romanus C. Omeh, Ibeabuchi Jude Ali, Cyril Ckekwube Adonu..... 19 – 30